Company intelligence / Profile preview

Ancora Global

Newark, California, United Statesancorabiotech.com ↗
Ownership
Private
Development stage
Other
01

Overview

Ancora Biotech develops multi-specific antibodies targeting major unmet needs in oncology, metabolic/inflammatory disease, and infectious disease. Its lead programs are at preclinical to early clinical stages. Notably, its spin-off TeneoTwo’s asset was acquired by AstraZeneca after promising early results in B-cell cancer therapy. The company leverages deep expertise from former leaders at Teneobio and has raised significant venture capital funding ($60M Series A).

Therapeutic areas
Metabolic DisordersPsychiatryInfectious DiseasesOncologyImmunology
Modalities
Monoclonal antibodyT cell engagerEnzyme inhibitorSmall molecule drug
Industry
Biotech
02

Drug pipeline

2 assets

TNB-738

1

1 more asset in the full pipeline.

03

Partnerships

Notable past partnerships via founders’ previous companies with Amgen, Celgene Corporation, Genmab A/S, Janssen Pharmaceuticals Inc., Merck KGaAAstraZeneca acquired one spin-off asset from Ancora’s portfolioInvestors include SR One and Lightspeed Venture Partners

Beyond the preview

Go deeper on Ancora Global.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ancora Global.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call